Table 1 Characteristics of all subjects andusage of microbiota-targeted agents in secondary infection and non-secondary infection groups of H7N9 patients
Characteristics | Secondary infection group | Non-secondary infection group | Healthy controls |
|---|---|---|---|
(n = 11) | (n = 14) | (n = 25) | |
Median age (years) | 64.5 | 48 | 58 |
Male:female (n) | 9:2 | 8:6 | 17:8 |
Median hospital stay (days) | 21.5 | 13 | -a |
Primary blood parameters at first follow-up: | Â | Â | Â |
Mean WBC (SD, 109cells per liter) | 8.0 (3.5) | 4.6 (3.3) | 5.7 (1.3) |
Mean CRP (SD, mg per liter) | 61.7 (72.3) | 42.8 (53.2) | - |
ALT median (25th–75th percentile, units per liter) | 38 (25–50) | 44 (19.5–114) | 16 (12.5–21) |
Antimicrobial usage: | Â | Â | - |
Cephalosporins (n) | 7 | 9 | - |
Carbapenems (n) | 6 | 1 | - |
β-Lactamase inhibitors and cephalosporins (n) | 4 | 3 | - |
β-Lactamase inhibitors and penicillins (n) | 9 | 5 | - |
Quinolones (n) | 10 | 8 | - |
Macrolides (n) | 4 | 1 | - |
Vancomycin (n) | 5 | 0 | - |
Tigecycline (n) | 4 | 0 | - |
Oxazolidinones (n) | 3 | 0 | - |
Phosphonomycin (n) | 1 | 1 | - |
Antifungalagents (n) | 1 | 0 | - |
Micro-ecological-targeted agents | Â | Â | - |
CBM588 (n) | 9 | 11 | - |
Bacillussubtilis- and E. faecium-coated enteric capsules (n) | 1 | 1 | - |
Lactulose (n) | 4 | 0 | - |
Infection with | Â | Â | - |
Canidia (n) | 7 | 0 | - |
Klebsiella pneumoniae, n | 6 | 0 | - |
Acinetobacter baumanii (n) | 5 | 0 | - |
Pseudomonas (n) | 5 | 0 | - |
Flavobacterium indologenes (n) | 1 | 0 | - |
Staphylococcus (n) | 2 | 0 | - |
Infections with mixed culture (n) | 7 | 0 | - |
Diarrhea (n) | 3 | 0 | - |